Complementary offerings will accelerate translation of biomarkers from research to the clinic driving new growth
互补性产品将加速生物标记从研究到临床的转化，推动新的增长

Expanded customer relationships and continuum of solution offerings maximize cross-selling opportunities across translational, academic and pharma applications
扩大的客户关系和连续的解决方案产品，最大限度地增加了转化、学术和制药应用领域的交叉销售机会

Expects to generate approximately $40 million of annual cost synergies by the end of 2026 with path to positive free cash flow generation in 2026
预计到 2026 年底，每年将产生约 4000 万美元的成本协同效益，并有望在 2026 年产生正的自由现金流

Combined cash position of approximately $175 million with no expected debt at closing to pursue future growth initiatives
合并现金头寸约为 1.75 亿美元，交易完成时预计无债务，可用于实施未来增长计划

BILLERICA, Mass. and MARLBOROUGH, Mass.,– January 10, 2025 –  Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ: AKYA), The Spatial Biology Company®, today announced a definitive merger agreement under which Quanterix will acquire Akoya in an all-stock transaction. The transaction will create the first integrated solution for ultra-sensitive detection of blood- and tissue-based protein biomarkers.
马萨诸塞州比勒里克和马萨诸塞州马尔堡--2025年1月10日--通过超灵敏生物标记物检测推动科学发现的Quanterix公司（纳斯达克股票代码：QTRX）和空间生物学公司Akoya Biosciences（纳斯达克股票代码：AKYA）今天宣布达成最终合并协议，Quanterix将通过全股票交易收购Akoya。这项交易将为基于血液和组织的蛋白质生物标记物的超灵敏检测提供首个集成解决方案。

“Liquid biopsy will eventually surpass the market size of all other diagnostics testing combined. Enabling early disease detection, before symptoms appear, using non-invasive methods is our mission and will be the majority of Quanterix’s long-term value,” said Masoud Toloue, PhD, Chief Executive Officer of Quanterix. “This transaction accelerates our progress by creating the first platform that lets researchers and clinicians track disease progression from tissue to blood. By starting with tissue and detecting early signs of complementary proteins in blood using leading ultra-sensitive SIMOA technology, we are uniquely positioned to speed up market development of new liquid biopsy tests.”
"液体活检的市场规模最终将超过所有其他诊断检测的总和。Quanterix首席执行官Masoud Toloue博士表示："在症状出现之前，利用非侵入性方法实现早期疾病检测是我们的使命，也是Quanterix长期价值的主要体现。"这项交易加速了我们的进展，因为我们创建了第一个平台，让研究人员和临床医生可以从组织到血液追踪疾病的进展。通过从组织入手，利用领先的超灵敏 SIMOA 技术检测血液中互补蛋白的早期迹象，我们在加快新型液体活检测试的市场开发方面具有得天独厚的优势。

Brian McKelligon, Chief Executive Officer of Akoya, said, “Joining forces with Quanterix marks a pivotal step in our journey to revolutionize the way we understand and treat disease. We are thrilled to be part of an established leader in the life science tools and diagnostics market that not only strengthens our presence in critical markets but also accelerates our ability to scale, innovate and ultimately bring to market products that impact human health. With the capital structure and significant synergies facilitated through this transaction, the combined company is well-positioned for future growth and profitability. We look forward to being part of the Quanterix team to better serve the needs of researchers and clinicians and bring substantial value to our customers and shareholders.”
Akoya首席执行官Brian McKelligon说："与Quanterix的合作标志着我们在彻底改变疾病认识和治疗方式的道路上迈出了关键的一步。我们很高兴能成为生命科学工具和诊断市场公认的领导者的一部分，这不仅加强了我们在关键市场的影响力，还加快了我们扩大规模、创新并最终将影响人类健康的产品推向市场的能力。凭借此次交易促成的资本结构和显著的协同效应，合并后的公司已为未来的增长和盈利能力做好了充分准备。我们期待成为 Quanterix 团队的一员，更好地满足研究人员和临床医生的需求，为我们的客户和股东带来巨大价值。

Strategic and Financial Benefits of the Combination
合并的战略和财务优势

• Creates first integrated solution for liquid and tissue proteomic biomarkers: The integration of Akoya’s spatial biology capabilities in tissue with Quanterix’s advanced tools for the ultra-sensitive detection of biomarkers in blood will establish the first fully integrated technology ecosystem to identify and measure biomarkers across tissue and blood. Quanterix will be better positioned to serve research customers and ultimately clinicians with a broader set of technologies to improve diagnostic relevance and accuracy and enhance patient outcomes through biomarker-driven treatment decisions.
  首创液体和组织蛋白质组生物标记物综合解决方案：Akoya的组织空间生物学能力与Quanterix的血液生物标志物超灵敏检测先进工具的整合，将建立首个全面整合的技术生态系统，用于识别和测量组织与血液中的生物标志物。Quanterix将更好地服务于研究客户，并最终为临床医生提供更广泛的技术，以提高诊断的相关性和准确性，并通过生物标志物驱动的治疗决策提高患者的治疗效果。
• Expands technology offering across high growth markets in neurology, oncology and immunology: With Quanterix’s industry-leading position in neurology and Akoya’s focus within oncology and immunology, Quanterix will expand its technology offerings across these high-growth markets. The addition of Akoya’s cutting-edge spatial biology capabilities will enable Quanterix to capitalize on growth opportunities in a $5 billion serviceable addressable market.
  在神经学、肿瘤学和免疫学等高增长市场拓展技术产品：凭借Quanterix在神经学领域的行业领先地位以及Akoya在肿瘤学和免疫学领域的专注，Quanterix将在这些高增长市场拓展其技术产品。Akoya尖端的空间生物学能力的加入，将使Quanterix能够在50亿美元的可服务市场中抓住增长机遇。
• Expanded lab services and clinical diagnostic market opportunity: Leveraging Akoya’s established clinical partnerships and CLIA-certified lab services, Quanterix is now strategically positioned to drive significant value creation through an expanded portfolio of lab service offerings. This collaboration establishes a clear path for Quanterix to participate in the rapidly emerging spatial biology clinical market, particularly in oncology.
  扩大实验室服务和临床诊断市场机会：利用Akoya已建立的临床合作关系和CLIA认证的实验室服务，Quanterix现在的战略定位是通过扩大实验室服务产品组合来创造巨大价值。此次合作为Quanterix参与迅速崛起的空间生物学临床市场（尤其是肿瘤学）开辟了一条清晰的道路。
• Increases commercial reach and maximizes cross-selling opportunities: Quanterix and Akoya have complementary offerings and deep customer relationships across discovery, translational, and clinical research. When offered as an integrated solution, Quanterix expects significant cross-selling opportunities to a combined 2,300 instrument install-base driving strong double-digit organic revenue growth in 2026.
  扩大商业覆盖面，最大限度地增加交叉销售机会：Quanterix和Akoya在发现、转化和临床研究领域拥有互补的产品和深厚的客户关系。Quanterix提供的是一个集成解决方案，预计在2026年，将有大量交叉销售机会，使合并后的2,300台仪器安装量实现强劲的两位数有机收入增长。
• Accelerates path to profitability through realization of substantial cost savings: The transaction is expected to generate approximately $40 million in annual cost synergies by the end of 2026, with $20 million expected to be realized within the first year following close. These cost savings will be driven primarily by the elimination of duplicative corporate structures, streamlined commercial infrastructure, increased operational efficiencies, process improvements and footprint optimization. The synergies will be additive to the cost savings initiatives already implemented by the two organizations. Quanterix’s previous cost initiatives combined with the expected cost synergies from the transaction are expected to accelerate its path to profitability, including generating positive free cash flow in 2026.
  通过大幅节约成本，加快实现盈利：预计到 2026 年底，该交易将产生约 4000 万美元的年度成本协同效应，其中 2000 万美元将在交易完成后的第一年内实现。这些成本节约将主要通过消除重复的公司结构、精简商业基础设施、提高运营效率、改进流程和优化足迹来实现。这些协同效应将与两家公司已经实施的成本节约措施相辅相成。Quanterix之前的成本节约措施与此次交易的预期成本协同效应相结合，有望加快其实现盈利的步伐，包括在2026年产生正的自由现金流。
• Significant combined cash balance: For the trailing 12 months ending September 30, 2024, the combined company generated revenue of approximately $220 million. With more than $300 million in combined cash today, Quanterix expects to have approximately $175 million in cash with no expected debt at the time of closing, after accounting for debt repayment, transaction costs, and a $20 million payment for its recently announced EMISSION acquisition. Quanterix will have financial flexibility to advance the Company’s global diagnostic testing infrastructure, including for Alzheimer’s disease and other growth opportunities such as Akoya’s advancement into the companion diagnostics segment.
  合并后现金余额可观：截至 2024 年 9 月 30 日的 12 个月内，合并后的公司收入约为 2.2 亿美元。目前，Quanterix 的合并现金超过 3 亿美元，在考虑债务偿还、交易成本以及最近宣布的 EMISSION 收购所需的 2,000 万美元付款后，Quanterix 预计在交易完成时将拥有约 1.75 亿美元现金，且预计不会有债务。Quanterix将拥有财务灵活性，以推进公司的全球诊断检测基础设施，包括阿尔茨海默氏症和其他增长机会，如Akoya进军辅助诊断领域。

Transaction Terms  交易条款

Under the terms of the agreement, which was approved by the Boards of Directors of both companies, Akoya shareholders will receive 0.318 shares of Quanterix common stock for each share of Akoya common stock owned. This represents a 19% premium to Akoya’s unaffected stock price on November 14, 2024, the last full trading day prior to Akoya’s announcement of its review of strategic alternatives.
根据双方董事会批准的协议条款，Akoya股东每持有1股Akoya普通股将获得0.318股Quanterix普通股。这比2024年11月14日（Akoya宣布审查战略选择前的最后一个完整交易日）Akoya未受影响的股票价格高出19%。

Following the close of the transaction, Quanterix shareholders will own approximately 70% of the combined company and Akoya shareholders will own approximately 30%, on a fully diluted basis.
交易完成后，Quanterix股东将拥有合并后公司约70%的股份，Akoya股东将拥有完全稀释后约30%的股份。

Timing, Approvals and Governance
时间安排、审批和管理

The transaction is expected to close in the second quarter of 2025, subject to approval by both companies’ shareholders, expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, and satisfaction of other customary closing conditions.
在获得两家公司股东批准、《1976 年哈特-斯科特-罗迪诺反托拉斯改进法》规定的等待期结束以及满足其他惯例成交条件的情况下，交易预计将于 2025 年第二季度完成。

Quanterix has entered into voting agreements supporting the transaction with certain shareholders owning more than 50% of Akoya’s common stock.
Quanterix已与持有Akoya 50%以上普通股的某些股东签订了支持交易的投票协议。

Following close, Masoud Toloue will serve as Chief Executive Officer and Vandana Sriram will serve as Chief Financial Officer. The combined company will continue to operate under the Quanterix name.
交易完成后，Masoud Toloue 将担任首席执行官，Vandana Sriram 将担任首席财务官。合并后的公司将继续以 Quanterix 的名称运营。

Upon closing, the Quanterix Board will consist of nine members. Two current Quanterix directors will resign, and Quanterix will appoint two directors designated by Akoya from their current Board.
交易完成后，Quanterix 董事会将由九名成员组成。两名Quanterix现任董事将辞职，Quanterix将从其现任董事会中任命两名由Akoya指定的董事。

Conference Call and Webcast
电话会议和网络广播

Quanterix will host a conference call and webcast today at 8:30 a.m. E.T. to discuss the transaction. For audio, use the following dial-in number and passcode: USA & Canada – Toll-Free (800) 715-9871 Conference ID: 9092934. Interested investors can also access the live webcast from the News & Events page within the Investors section of the Quanterix website at http://www.quanterix.com.
Quanterix 将于美国东部时间今天上午 8:30 举行电话会议和网络直播，讨论此次交易。音频请使用以下拨号和密码：美国和加拿大 - 免费电话 (800) 715-9871 会议 ID：9092934。感兴趣的投资者也可以从 Quanterix 网站 http://www.quanterix.com 投资者版块的新闻与活动页面访问网络直播。

Advisors  顾问

Goldman Sachs & Co. LLC is serving as financial advisor to Quanterix and Covington & Burling LLP is serving as its legal counsel. Perella Weinberg Partners LP is serving as financial advisor to Akoya and DLA Piper LLP is serving as its legal counsel.
高盛公司（Goldman Sachs & Co.LLC担任Quanterix的财务顾问，Covington & Burling LLP担任其法律顾问。Perella Weinberg Partners LP担任Akoya的财务顾问，DLA Piper LLP担任其法律顾问。

About Quanterix  关于 Quanterix

From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa^® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 3,100 peer-reviewed journals.
从发现到诊断，Quanterix的超灵敏生物标记物检测技术正在推动突破性进展，而这只有通过其无与伦比的灵敏度和灵活性才能实现。公司的Simoa ^®  技术为早期检测血液、血清或血浆中的生物标记物提供了黄金标准，能够定量检测远低于定量水平（LoQ）的蛋白质。其业界领先的精密仪器、数字免疫测定技术和通过 CLIA 认证的加速器实验室为神经病学、肿瘤学、免疫学、心脏病学和传染病学领域的研究提供了支持，促进了对疾病的理解和管理。近二十年来，Quanterix一直是科学界值得信赖的合作伙伴，其研究成果发表在3100多份同行评审期刊上。

About Akoya Biosciences  关于 Akoya 生物科学公司

As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The Company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler®, PhenoImager® Fusion and PhenoImager® HT Instruments. To learn more about Akoya, visit www.akoyabio.com.
作为空间生物学公司（The Spatial Biology Company®），Akoya Biosciences的使命是通过空间表型的力量，为生物学世界和人类健康带来语境。公司提供全面的单细胞成像解决方案，使研究人员能够根据空间背景对细胞进行表型，并直观地了解细胞是如何组织和相互作用以影响疾病进展和治疗反应的。Akoya提供一整套空间表型解决方案，以满足研究人员在发现、转化和临床研究方面的不同需求：PhenoCode™ Panels和PhenoCycler®、PhenoImager® Fusion和PhenoImager® HT仪器。欲了解有关Akoya的更多信息，请访问 www.akoyabio.com 。

IMPORTANT ADDITIONAL INFORMATION
重要补充信息

In connection with the proposed transaction, Quanterix will file with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4 (the “registration statement”), which will contain a joint proxy statement of Quanterix and Akoya and a prospectus of Quanterix (the “joint proxy statement/prospectus”), and each of Quanterix and Akoya may file with the SEC other relevant documents regarding the proposed transaction. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT AND THE JOINT PROXY STATEMENT/PROSPECTUS CAREFULLY AND IN THEIR ENTIRETY AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC BY QUANTERIX AND AKOYA, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT QUANTERIX, AKOYA AND THE PROPOSED TRANSACTION. A definitive copy of the joint proxy statement/prospectus will be mailed to Quanterix and Akoya stockholders when that document is final. Investors and security holders will be able to obtain the registration statement and the joint proxy statement/prospectus, as well as other filings containing information about Quanterix and Akoya, free of charge from Quanterix or Akoya or from the SEC’s website when they are filed. The documents filed by Quanterix with the SEC may be obtained free of charge at Quanterix’s website, at www.quanterix.com, or by requesting them by mail at Quanterix Investor Relations, 900 Middlesex Turnpike, Billerica, MA 01821. The documents filed by Akoya with the SEC may be obtained free of charge at Akoya’s website, at www.akoyabio.com, or by requesting them by mail at Akoya Biosciences, 100 Campus Drive, 6^th Floor, ATTN: Chief Legal Officer, Marlborough, MA 01752.
就拟议的交易而言，Quanterix将向美国证券交易委员会（"SEC"）提交S-4表格登记声明（"登记声明"），其中将包含Quanterix和Akoya的联合委托声明和Quanterix的招股说明书（"联合委托声明/招股说明书"），Quanterix和Akoya还可能向SEC提交有关拟议交易的其他相关文件。请投资者和证券持有人仔细阅读注册声明和联合代理声明/招股说明书全文，以及Quanterix和Akoya向美国证券交易委员会提交的任何其他相关文件，以及这些文件的任何修订或补充文件，因为它们将包含有关Quanterix、Akoya和拟议交易的重要信息。联合代理声明/招股说明书的最终版本将在文件定稿后邮寄给Quanterix和Akoya股东。投资者和证券持有人可免费从Quanterix或Akoya或美国证券交易委员会网站获取注册声明和联合委托声明/招股说明书，以及包含Quanterix和Akoya信息的其他文件。Quanterix向美国证券交易委员会提交的文件可从Quanterix网站免费获取，网址是：www.quanterix.com，或通过邮寄方式向Quanterix投资者关系部索取，地址是：900 Middlesex Turnpike, Billerica, MA 01821。Akoya向美国证券交易委员会提交的文件可从Akoya网站免费获取，网址是：www.akoyabio.com，或通过邮寄方式向Akoya Biosciences索取，地址是：100 Campus Drive, 6 ^th Floor, ATTN: Chief Legal Officer, Marlborough, MA 01752。

PARTICIPANTS IN THE SOLICITATION
招标参与者

Quanterix and Akoya and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Quanterix or Akoya in respect of the proposed transaction. Information about Quanterix’s directors and executive officers is available in Quanterix’s proxy statement dated April 15, 2024, for its 2024 Annual Meeting of Stockholders, and other documents filed by Quanterix with the SEC. Information about Akoya’s directors and executive officers is available in Akoya’s proxy statement dated April 23, 2024, for its 2024 Annual Meeting of Stockholders, and other documents filed by Akoya with the SEC. Other information regarding the persons who may, under the rules of the SEC, be deemed participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed transaction when they become available. Investors should read the joint proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from Quanterix or Akoya as indicated above.
Quanterix和Akoya及其各自的某些董事和执行官可能会被视为就拟议交易向Quanterix或Akoya股东征求委托书的参与者。有关Quanterix董事和执行官的信息，请参见Quanterix于2024年4月15日发布的2024年度股东大会代理声明，以及Quanterix向美国证券交易委员会提交的其他文件。有关Akoya董事和高管的信息，请参阅Akoya于2024年4月23日发布的2024年度股东大会代理声明，以及Akoya向美国证券交易委员会提交的其他文件。根据美国证券交易委员会的规定，可能被视为代理征集参与者的其他人员的相关信息，以及他们通过持有证券或其他方式所拥有的直接和间接利益的描述，将载于联合代理声明/招股说明书和其他相关材料中，这些材料将在拟议交易完成后提交给美国证券交易委员会。投资者在做出任何投票或投资决定之前，应仔细阅读联合代理声明/招股说明书。如上所述，您可以从 Quanterix 或 Akoya 免费获取这些文件的副本。

NO OFFER OR SOLICITATION  无要约或邀约

This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval with respect to the proposed merger of Quanterix and Akoya, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.
如果在任何司法管辖区，根据该司法管辖区的证券法，在注册或取得资格之前，要约、邀约或销售证券属于非法行为，则本通信不得构成销售要约或购买要约的邀约，也不得构成就Quanterix和Akoya的拟议合并征求任何投票或批准的邀约。除非招股说明书符合经修订的《1933 年美国证券法》第 10 条的要求，否则不得进行任何证券发售。

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
关于前瞻性声明的警示性声明

Statements included in this communication which are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on, among other things, projections as to the anticipated benefits of the proposed transaction as well as statements regarding the impact of the proposed transaction on Quanterix’s and Akoya’s business and future financial and operating results, the amount and timing of synergies from the proposed transaction and the closing date for the proposed transaction. Words and phrases such as “may,” “approximately,” “continue,” “should,” “expects,” “projects,” “anticipates,” “is likely,” “look ahead,” “look forward,” “believes,” “will,” “intends,” “estimates,” “strategy,” “plan,” “could,” “potential,” “possible” and variations of such words and similar expressions are intended to identify such forward-looking statements. Quanterix and Akoya caution readers that forward-looking statements are subject to certain risks and uncertainties that are difficult to predict with regard to, among other things, timing, extent, likelihood and degree of occurrence, which could cause actual results to differ materially from anticipated results. Such risks and uncertainties include, among others, the following possibilities: the occurrence of any event, change or other circumstances that could give rise to the right of one or both of the parties to terminate the definitive merger agreement entered into between Quanterix and Akoya; the outcome of any legal proceedings that may be instituted against Quanterix or Akoya; the failure to obtain necessary regulatory approvals (and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the proposed transaction) and stockholder approvals or to satisfy any of the other conditions to the proposed transaction on a timely basis or at all; the possibility that the anticipated benefits and synergies of the proposed transaction are not realized when expected or at all, including as a result of the impact of, or problems arising from, the integration of the two companies or as a result of the strength of the economy and competitive factors in the areas where Quanterix and Akoya do business; the possibility that the proposed transaction may be more expensive to complete than anticipated; diversion of management’s attention from ongoing business operations and opportunities; potential adverse reactions or changes to business or employee relationships, including those resulting from the announcement or completion of the proposed transaction; changes in Quanterix’s share price before the closing of the proposed transaction; risks relating to the potential dilutive effect of shares of Quanterix common stock to be issued in the proposed transaction; and other factors that may affect future results of Quanterix, Akoya and the combined company. Additional factors that could cause results to differ materially from those described above can be found in Quanterix’s Annual Report on Form 10-K for the year ended December 31, 2023, as amended, Akoya’s Annual Report on Form 10-K for the year ended December 31, 2023, and in other documents Quanterix and Akoya file with the SEC, which are available on the SEC’s website at www.sec.gov.
根据1933年《证券法》（修订版）第27A条和1934年《证券交易法》（修订版）第21E条规定的安全港条款，本通报中包含的非历史性陈述或与当前事实无关的陈述旨在成为前瞻性陈述，并在此被确定为前瞻性陈述。前瞻性声明的依据包括：对拟议交易预期收益的预测；拟议交易对Quanterix和Akoya业务及未来财务和经营业绩的影响；拟议交易协同效应的金额和时间；以及拟议交易的完成日期。可能"、"大约"、"继续"、"应该"、"预期"、"计划"、"预计"、"很可能"、"展望"、"向前看"、"相信"、"将要"、"打算"、"估计"、"战略"、"计划"、"可能"、"潜在"、"可能 "等词语和短语以及此类词语和类似表述的变体旨在识别此类前瞻性表述。Quanterix和Akoya告诫读者，前瞻性声明受某些风险和不确定性因素的影响，这些风险和不确定性因素在时间、范围、可能性和发生程度等方面难以预测，可能导致实际结果与预期结果存在实质性差异。 此类风险和不确定性主要包括以下可能性：发生任何可能导致一方或双方有权终止Quanterix和Akoya之间签订的最终合并协议的事件、变化或其他情况；可能针对Quanterix或Akoya提起的任何法律诉讼的结果；未能及时或完全获得必要的监管批准（以及此类批准可能导致附加条件，从而对合并后的公司或拟议交易的预期收益产生不利影响的风险）和股东批准，或未能满足拟议交易的任何其他条件；拟议交易的预期收益和协同效应可能无法如期实现或根本无法实现，包括由于两家公司的整合所产生的影响或问题，或由于Quanterix和Akoya业务所在地区的经济实力和竞争因素所造成的影响或问题；完成拟议交易的成本可能高于预期；管理层的注意力从正在进行的业务运营和机会上转移；业务或员工关系的潜在不利反应或变化，包括因宣布或完成拟议交易而产生的不利反应或变化；拟议交易完成前Quanterix股价的变化；与拟议交易中发行的Quanterix普通股的潜在稀释效应有关的风险；以及可能影响Quanterix、Akoya和合并后公司未来业绩的其他因素。 其他可能导致结果与上述结果存在实质性差异的因素，请参见Quanterix截至2023年12月31日的10-K表年报（经修订）、Akoya截至2023年12月31日的10-K表年报以及Quanterix和Akoya向美国证券交易委员会提交的其他文件，这些文件可在美国证券交易委员会网站www.sec.gov。

All forward-looking statements, expressed or implied, included in this communication are expressly qualified in their entirety by the cautionary statements contained or referred to herein. If one or more events related to these or other risks or uncertainties materialize, or if Quanterix’s or Akoya’s underlying assumptions prove to be incorrect, actual results may differ materially from what Quanterix and Akoya anticipate. Quanterix and Akoya caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made and are based on information available at that time. Neither Quanterix nor Akoya assumes any obligation to update or otherwise revise any forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements were made or to reflect the occurrence of unanticipated events except as required by federal securities laws.
本新闻稿中包含的所有前瞻性陈述，无论明示或暗示，均受到本新闻稿中包含或提及的警示性陈述的明确限制。如果与这些或其他风险或不确定因素相关的一个或多个事件成为现实，或者Quanterix或Akoya的基本假设被证明是不正确的，则实际结果可能与Quanterix和Akoya的预期大相径庭。Quanterix公司和Akoya公司提醒读者不要过分依赖任何此类前瞻性声明，这些声明仅涉及声明发布当日的情况，并以当时可获得的信息为基础。除非联邦证券法另有规定，否则Quanterix和Akoya没有义务更新或修改任何前瞻性声明，以反映前瞻性声明作出之日以后发生的情况或事件，或反映意外事件的发生。

Quanterix Contacts  Quanterix 联系人

Media  媒体
Marissa Klaassen  玛丽莎-克拉森
media@quanterix.com

Or  或者

Jim Golden / Tali Epstein
吉姆-戈登 / 塔利-爱泼斯坦
Collected Strategies  策略集锦
QTRX-CS@collectedstrategies.com

Investor Relations  投资者关系
Joshua Young  约书亚-扬
ir@quanterix.com

Akoya Contacts  Akoya 触点

Media  媒体
Christine Quern  克莉丝汀-昆恩
media@akoyabio.com

Investors  投资者
Priyam Shah  普里亚姆-沙阿
investors@akoyabio.com